Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.
Quick Facts
What This Study Found
GLP-1 receptor agonists may worsen diabetic retinopathy in some patients, especially semaglutide, likely from rapid blood sugar improvement. The cardiovascular benefits outweigh this risk when ophthalmology follow-up is maintained.
Key Numbers
Some worsening of diabetic retinopathy noted in studies, particularly with semaglutide; macrovascular benefits prioritized over microvascular risk
How They Did This
Brief clinical review of GLP-1 RA effects on diabetic retinopathy, covering trial data and clinical recommendations.
Why This Research Matters
Eye doctors are seeing more patients on GLP-1 drugs. Knowing that rapid glycemic improvement can temporarily worsen retinopathy helps plan monitoring and prevents unnecessary drug discontinuation.
What This Study Doesn't Tell Us
Brief review without systematic methodology. Retinopathy worsening data come from subgroup analyses of larger trials. Mechanism not fully established.
Trust & Context
- Original Title:
- Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.
- Published In:
- International ophthalmology clinics, 65(1), 23-26 (2025)
- Database ID:
- RPEP-13398
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13398APA
Samanta, Anindya; Bordbar, Darius D; Weng, Christina Y; Chancellor, John R. (2025). Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.. International ophthalmology clinics, 65(1), 23-26. https://doi.org/10.1097/IIO.0000000000000541
MLA
Samanta, Anindya, et al. "Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.." International ophthalmology clinics, 2025. https://doi.org/10.1097/IIO.0000000000000541
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like Peptide-1 Receptor Agonists in the Management ..." RPEP-13398. Retrieved from https://rethinkpeptides.com/research/samanta-2025-glucagonlike-peptide1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.